Company Overview - Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for oncology, specifically for multiple solid tumor indications [3] - The company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor, which has differentiated pharmacokinetic properties compared to other therapies targeting PI3K or mTOR [3] Clinical Trials - A Phase 3 clinical trial, VIKTORIA-1, is currently enrolling patients to evaluate gedatolisib in combination with fulvestrant with or without palbociclib for HR+/HER2- advanced breast cancer [3] - A Phase 1b/2 clinical trial, CELC-G-201, is ongoing to assess gedatolisib in combination with darolutamide for metastatic castration-resistant prostate cancer [3] - A second Phase 3 clinical trial, VIKTORIA-2, is expected to begin enrolling patients in Q2 2025, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for HR+/HER2- advanced breast cancer [3] Financial Results Announcement - Celcuity will release its financial results for Q4 and full year 2024 after market close on March 31, 2025, followed by a webcast/teleconference at 4:30 p.m. Eastern Time [1]
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call